Adcendo
Business Services · Denmark · 11-50 Employees
View Company Info for Free
Overview
Headquarters
C/o Symbion Frederiksberg 215, København...Website
www.adcendo.comRevenue
$5.3 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Adcendo
Adcendo is a clinical-stage biotechnology company focused on developing antibody-drug conjugate therapies for the treatment of cancer. The company works on advancing targeted therapies by combining expertise in biology, chemistry, and clinical development to address unmet medical needs in oncology. It collaborates with scientific, clinical, and industry partners to support research and development efforts. Its approach emphasizes innovation in targeted drug design and precision-based treatment strategies. It focuses on advancing targeted cancer therapies through innovative antibody-based platforms. The company operates within the life sciences sector, emphasizing precision medicine and clinical research. Its activities are centered on early-stage development rather than large-scale pharmaceutical manufacturing.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Adcendo your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Adcendo is spiking on competitors!
Product Launch: Get notified when Adcendo launches new products
Earning: See what the market has to say on Adcendo recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Adcendo
Check if Adcendo has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Adcendo has new funding data
Adcendo, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Adcendo had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Adcendo
Find 2 more new buyers
Company Profile Activity
Activity Insights
Adcendo is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Adcendo is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Adcendo.
Adcendo financials insights
Gather financial insights about Adcendo, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series A
$106M
Series B
$135M
2026
Series C
$75M
Adcendo Tech Stack
A closer look at the technologies used by Adcendo
See more technologies
Most Recent Scoops
Funding
Funding
New Hire
Executive Move
Executive Moves, New Hire
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
Adcendo News & Media
Adcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA® (Pembrolizumab) in a Phase Ib Study in Patients with Advanced Solid Tumors
Combining a potential best-in-class tissue factor-targeting ADC with anti-PD-1 therapy may enhance the anti-tumor activity of the combination due to the complementary nature of the two mechanisms Adcendo will sponsor the Phase 1b clinical trial and MSD will provide pembrolizumab...Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates
ADCE-T02, a potential best-in-class Tissue Factor targeted antibody-drug conjugate (ADC), enters cohort expansion portion of the Tiffany-01 study in advanced solid tumors Two ADCE-T02 publications highlighting important preclinical results at the 2026 AACR Annual Meeting ADCE-D01, a...Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates
ADCE-T02, a potential best-in-class Tissue Factor targeted antibody-drug conjugate (ADC), enters cohort expansion portion of the Tiffany-01 study in advanced solid tumors Two ADCE-T02 publications highlighting important preclinical results at the 2026 AACR Annual Meeting ADCE-D01, a...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Adcendo
Sign Up For FreeTo access detailed company insights
Adcendo is a clinical-stage biotechnology company focused on developing antibody-drug conjugate therapies for the treatment of cancer. The company works on advancing targeted therapies by combining expertise in biology, chemistry, and clinical development to address unmet medical needs in oncology. It collaborates with scientific, clinical, and ind... Read More
